Abbott Again Moves To Block Generic Version Of Zemplar

Law360, New York (April 26, 2012, 2:57 PM EDT) -- Abbott Laboratories on Wednesday again went to court to defend its Zemplar injectable, accusing Strides Arcolab Ltd. of developing a generic version of the kidney disease treatment that infringes Abbott's patents.

In a suit launched in Delaware federal court, Abbott and partner Wisconsin Alumni Research Foundation accused Strides and subsidiary Agila Specialties Pvt. Ltd. of filing an abbreviated new drug application covering a Zemplar clone that infringes a trio of the plaintiffs' patents.

“Strides has committed and will commit acts of infringement of the patents-in-suit that...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.